What is the cerebrospinal fluid penetration of aztreonam?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 29, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Aztreonam CSF Penetration

Aztreonam achieves limited but measurable CSF concentrations in inflamed meninges, with penetration of approximately 23% and CSF levels of 3-16 mcg/mL after a 2g IV dose, which exceeds the MIC for most susceptible Gram-negative organisms but is generally insufficient for reliable CNS infection treatment as monotherapy.

CSF Penetration Data

According to FDA labeling, aztreonam reaches CSF concentrations of 3 mcg/mL (range 0.9-4.3 mcg/mL) in patients with inflamed meninges 0.9-4.3 hours after a single 2g IV dose 1. This represents meaningful penetration only when meningeal inflammation is present.

Key Pharmacokinetic Parameters:

  • Penetration rate in inflamed meninges: 23% of serum concentration 2
  • CSF levels after 2g IV dose: 3.5-62 mcg/mL depending on timing and degree of inflammation 3
  • Pediatric penetration: 17.3% in children with inflamed meninges after 30 mg/kg dose 4
  • Minimal penetration without inflammation: Only 1.1-4.7 mcg/mL in non-infected rabbits 5

Clinical Implications

The CSF concentrations achieved are adequate for organisms with low MICs (most Enterobacterales, H. influenzae) but marginal for organisms like Pseudomonas aeruginosa, which often have higher MICs. In experimental meningitis models, aztreonam demonstrated rapid bactericidal activity against H. influenzae and E. coli, outperforming ampicillin and gentamicin respectively 2.

Comparative Context:

For reference, other antibiotics achieve the following CSF penetration in inflamed meninges:

  • Linezolid: 66% 6
  • Fluoroquinolones: 38-44% 7
  • Aminoglycosides: 14-20% 7
  • Vancomycin: 5% 6

Practical Considerations

Aztreonam is not recommended as monotherapy for CNS infections. While it achieves therapeutic levels against susceptible Gram-negative organisms in inflamed meninges, the penetration is insufficient for reliable empiric coverage. The drug may have a role in combination therapy for multidrug-resistant Gram-negative meningitis when combined with other agents that have better CNS penetration.

A recent case report demonstrated adequate aztreonam CSF concentrations when combined with ceftazidime-avibactam for post-neurosurgical meningitis, with therapeutic drug monitoring confirming adequate levels throughout treatment 8.

Critical Caveats:

  • Penetration is inflammation-dependent—as meningitis resolves, CSF levels decline
  • The 2g dose is necessary for adequate CSF levels; lower doses produce subtherapeutic concentrations
  • Aztreonam does not cross-react with other β-lactams except ceftazidime (shared R-group side chain) 9
  • Renal function significantly affects serum and CSF levels; dose adjustment required in renal impairment 1

References

4
Research

Single-dose pharmacokinetics of aztreonam in pediatric patients.

Antimicrobial agents and chemotherapy, 1984

9
Guideline

the diagnosis and management of anaphylaxis: an updated practice parameter.

Journal of Allergy and Clinical Immunology, 2005

Related Questions

When should aztreonam be preferred?
What are the indications, dosing regimens, and treatment duration for aztreonam in adult patients with normal, moderately impaired, and severely impaired renal function?
What are the indications, dosing recommendations, and renal dose adjustments for aztreonam in adult and pediatric patients?
What is the appropriate home intravenous dosing and administration protocol for aztreonam in an adult with normal renal function?
What aztreonam dose and dosing interval should be used in an elderly female patient with an estimated glomerular filtration rate of 87 mL/min who has an infected heel wound?
For a patient with E. coli bacteremia positive for a CTX‑M (extended‑spectrum β‑lactamase) gene, should contact isolation be implemented and what are the appropriate antibiotic choices?
What is the recommended dosing and monitoring for ketamine in an adult patient with acute agitation who has no contraindications such as uncontrolled hypertension, severe cardiac disease, known psychotic disorder, or a history of ketamine abuse?
What is the most appropriate next step in evaluation and management for a 68-year-old man with a 7‑week history of mid‑thoracic back pain radiating to the umbilicus, worsened by movement and at night, anemia (hemoglobin 8 g/dL) and mild hypercalcemia (serum calcium 10.8 mg/dL)?
What intervention most effectively reduces the likelihood of ventilator-associated pneumonia?
What should be included in the pre‑operative surgical work‑up (complete blood count, renal function tests, liver function tests, lipid profile) and why is vitamin K administered before surgery for gallstone disease?
How should cystitis cystica glandularis be evaluated and managed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.